NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET

Company Participants

Tom Johnson - Investor Relations

Stephen Willard - Chief Executive Officer

Seth Van Voorhees - Chief Financial Officer & Treasurer

Robert Besthof - Head of Operations & Chief Commercial Officer

Conference Call Participants

Vernon Bernardino - HC Wainwright

Operator

Good day, and welcome to the NRx Pharmaceuticals Second Quarter 2022 Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Tom Johnson. Please, go ahead.

Tom Johnson

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call or forward-looking statements under US Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call's speak only as the date hereof. And the company undertakes no obligation to update or revise these forward-looking statements. Information presented on this call is contained in the press release issued earlier today and in the company's Form 10-Q that we're filing today, which will be accessed from the investor's page of the NRx Pharmaceuticals, Inc. website.

Joining me on today's call from NRx Pharmaceuticals are Stephen Willard, Chief Executive Officer, and Seth Van Voorhees, Chief Financial Officer and Treasurer. Stephen will provide a summary of the company's progress before turning it over to Seth for a review of the company's financial results. Following their prepared remarks, Stephen and Seth will be joined by Robert Besthof, Head of Operations and Chief Commercial Officer, to address investor questions.

I will now turn the call over to Stephen.

Stephen Willard

Thank you, Tom. Good morning, everyone, and thank you for joining us today. I'm excited to host my first quarterly results call as CEO of NRx Pharmaceuticals. I spent a large portion of my career in both private industry and public service, dedicated to advancing compelling science to benefit people and to build value for shareholders.

When I decided to assume the leadership role at NRx, I saw an opportunity to do both. Joining me in this endeavor are Seth Van Voorhees, our new Chief Financial Officer; Jonathan Javitt, our Chief Scientific Officer; and Robert Besthof, Head of Operations and Chief Commercial Officer. We appreciate your attendance today and look forward to engaging with you on this and future calls as we work to realize the opportunities before us.